Bader Abu Ghalyoun, MD
Interventional Cardiology · Stockton, CANPI 1740492214
Payments from drug & device makers
Across 271 payments — averaging $40.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$1K
- Novartis$871
- Abbott$840
- Novo Nordisk$531
- Boehringer Ingelheim$441
- plus $4K from 26 others
What the payments were for
- Consulting fees$2002%
- Grants$1,10510%
- Travel & lodging$3,60033%
- Food & beverage$5,90054%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 27 | $3,543 |
| Boston Scientific | 2 | $1,125 |
| Novartis | 48 | $871 |
| Abbott | 8 | $840 |
| Novo Nordisk | 20 | $531 |
| Boehringer Ingelheim | 23 | $441 |
| Abiomed | 7 | $438 |
| Johnson & Johnson | 22 | $436 |
| Bayer | 13 | $428 |
| Merck | 16 | $309 |
| Amgen | 13 | $265 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $200 |
| AstraZeneca | 9 | $171 |
| Philips North America LLC | 6 | $167 |
| Pfizer | 6 | $150 |
| Acist Medical Systems, Inc. | 1 | $147 |
| Shockwave Medical, Inc | 4 | $116 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Impulse Dynamics (USA) Inc. | 3 | $82 |
| Lexicon Pharmaceuticals, Inc. | 5 | $82 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $61 |
| Tactile Systems Technology Inc | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Lilly USA, LLC | 2 | $47 |
| Asahi Intecc USA, Inc. | 1 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Chiesi USA, Inc. | 1 | $26 |
| Resmed Corp | 1 | $25 |
| Cook Medical LLC | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,858 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 710 | $675,203 |
| EliquisApixaban | 329 | $344,107 |
| XareltoRivaroxaban | 305 | $310,498 |
| JardianceEmpagliflozin | 323 | $302,881 |
| FarxigaDapagliflozin Propanediol | 139 | $114,651 |
| Repatha SureclickEvolocumab | 67 | $60,644 |
| MultaqDronedarone Hcl | 15 | $29,028 |
| BrilintaTicagrelor | 33 | $17,180 |
| DapagliflozinDapagliflozin Propanediol | 22 | $16,999 |
| Atorvastatin Calcium | 861 | $9,654 |
| Praluent PenAlirocumab | 18 | $9,456 |
| Carvedilol | 1,056 | $9,305 |
| Metoprolol Succinate | 571 | $8,084 |
| Amiodarone Hcl | 63 | $7,473 |
| Rosuvastatin Calcium | 335 | $7,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $871 | $675,203710 claims |
| PfizerEliquis | $150 | $344,107329 claims |
| Johnson & JohnsonXarelto | $436 | $310,498305 claims |
| Boehringer IngelheimJardiance | $441 | $302,881323 claims |
| AstraZenecaFarxiga, Brilinta | $171 | $131,831172 claims |
| Sanofi-aventis U.S. LLCMultaq | $92 | $29,02815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Stockton
- Cyrus BuhariStockton$324K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.